VABOMERE Shows Higher Cure Rate in Patients with CRE Infections Vs. Best Available Therapy
OCT 18, 2017 | CONTAGION® EDITORIAL STAFF
Michael N. Dudley, PharmD, senior vice president and head of R&D at the Medicines Company, discusses the results of the TANGO II study of VABOMERE, a new beta-lactam that combines meropenem and vaborbactam. In patients with carbapenem-resistant Enterobacteriaceae (CRE), VABOMERE was associated with a higher overall cure and lower mortality compared with the best available therapy.
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
The new test can differentiate between Lyme disease and 7 other tick-borne diseases.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512